米国における胃腸薬の市場

Abstract

This report covers a range of products designed specifically for relief from gastrointestinal ailments, including antacids, laxatives, stomach remedies and anti-diarrheals.

In 2006, there were an estimated 62 million sufferers of gastrointestinal (GI) ailments. Poor diet and stress-inducing lifestyles also factor into sales. Many consumers are following the growing trend to diagnose and treat themselves when minor GI ailments occur, which has aided sales. Hispanic consumers appear to be a very viable demographic for manufacturers of over-the-counter remedies, as their population and spending power increases rapidly. A significant number of Hispanics and other ethnicities also lack health insurance, and in many cases must turn to over-the-counter medications to alleviate symptoms. The cornerstone of the market remains aging consumers, who report suffering from GI disorders and using remedies more than their younger counterparts.

Major innovation is scarce in the market, despite 130 new products or line extensions between 2001 and 2006. Among the new product trends are chewable tablets, more palatable flavoring, and combination products that offer relief for two or more symptoms. Most of the growth in the market has come from prescription switches, mainly Procter & Gamble's Prilosec tablets, and to a lesser degree Pfizer's Zantac 150 tablets. Without the sales of these products, the market would not exhibit the growth it has between 2004 and 2006.

The future of the market appears strong, mostly because the number of consumers aged 45 and older, the period in age when GI disorders begin to appear more frequently, is forecast to increase more than younger demographics. Also, a relaxation of FDA standards on prescription switches may allow more products to go OTC, despite more stringent laws on direct-to-consumer advertising and recent litigation involving switches in other OTC markets. Switches traditionally aid the overall size of the market. Hispanic population and spending power numbers are expected to increase in the coming years as well, heralding further participation in the market.

In this report, Mintel clearly identifies the principal external factors driving or curtailing growth. Exclusive consumer research reveals the attitudes, needs and behavior of consumers, with analysis broken down both by demographic characteristics, and by segment.

Six years of specific sales data provide a factual and impartial presentation of the market as a whole. Mintel also evaluates the performance of individual sectors in the market, and provides information about the major companies and brands. Using the SPSS forecasting package, Mintel creates a five-year forecast of U.S. retail sales, revealing potential opportunities for growth and product development.

This report contains US IRI InfoScan data.

Table of Contents

• Introduction and Abbreviations
• Introduction
• Definition
• Abbreviations and terms
• Abbreviations
• Terms
• Executive Summary
• Age, ethnicity, and lifestyle combine with self-care and switches
• Chewable tablets, flavoring, and combo products help grow market
• Antacids dominate segments
• Six manufacturers dominate
• TV, print begin to share with Web advertising
• The consumer
• Aging and ethnic populations, switches, retail environment impact the future
• Market forecast
• Market Drivers
• pIncidence of gastrointestinal ailments increases
  • Figure 1: U.S. population projections and number of GI ailment sufferers, by age, 2001-11
• Aging population equals windfall of GI industry
  • Figure 2: Incidence of gastrointestinal ailments, by type of ailment, by age, 2005
• Diet and stress contribute to incidence
  • Figure 3: Attitudes towards diet, September 2003-05
• Prescription switches to OTC
• Direct-to-consumer advertising boosts awareness
• Self-diagnosis and self-care continue momentum
• Insurance co-pay hikes
• Hispanic: A new generation of GI sufferers
  • Figure 4: U.S. Hispanic population projections and number of GI ailment sufferers, by age, 2001-11
• Market Size and Trends
• Market size
  • Figure 5: Total U.S. FDM retail sales of gastrointestinal remedies, at current and constant prices, 2001-06
  • Figure 6: Graph: Total U.S. FDM retail sales of gastrointestinal remedies, at current and constant prices,
• Market trends
  • Figure 7: New gastrointestinal remedy product launches by product type, 2001-06
  • Figure 8: Number of new gastrointestinal remedy products by price, 2001-06
• Market Segmentation
• Overview
  • Figure 9: FDM sales of gastrointestinal remedies, segmented by type, 2004 and 2006
  • Figure 10: Graph: FDM sales of gastrointestinal remedies, segmented by type, 2004 and 2006
• Antacids
  • Figure 11: FDM sales of antacids, at current and constant prices, 2001-06
• Laxatives
  • Figure 12: FDM sales of laxatives, at current and constant prices, 2001-06
• Stomach remedies
  • Figure 13: FDM sales of stomach remedies, at current and constant prices, 2001-06
• Anti-diarrheals
  • Figure 14: FDM sales of anti-diarrheals, at current and constant prices, 2001-06
• Supply Structure
• Companies and brands
  • Figure 15: Manufacturer FDM sales of gastrointestinal remedies in the U.S., 2004 and 2006
• Antacids
  • Figure 16: Manufacturer brand FDM sales of antacids in the U.S., 2004 and 2006
• Laxatives
  • Figure 17: Manufacturer brand FDM sales of laxatives in the U.S., 2004 and 2006
• Stomach remedies
  • Figure 18: Manufacturer brand FDM sales of stomach remedies in the U.S., 2004 and 2006
• Anti-diarrheals
  • Figure 19: Manufacturer brand FDM sales of anti-diarrheals in the U.S., 2004 and 2006
• Company profiles
• Procter & Gamble
• Johnson & Johnson
• GlaxoSmithKline
• Novartis Consumer Health
• Pfizer, Inc.
• Other companies
• Advertising and Promotion
• Introduction
  • Figure 20: Estimated online streaming media expenditures, 2004-10
• Procter & Gamble
  • Figure 21: Pepto Bismol ad featuring young basketball players, 2006
• GlaxoSmithKline
  • Figure 22: Tums ad featuring roadside diners, 2006
• Johnson & Johnson-Merck
  • Figure 23: Pepcid AC ad featuring "Jim" the adventurous eater, 2006
• Novartis
  • Figure 24: Maalox ad feauturing, 2006
• Pfizer
  • Figure 25: Rolaids ad featuring deflating tires, balloons, 2006
• McNeil
• Retail Distribution
• Introduction
  • Figure 26: U.S. retail FDM sales of gastrointestinal remedies, by channel, 2004 and 2006
• Drug stores
  • Figure 27: U.S. mass merchandiser and club store sales of GI remedies, at current and constant prices,
• Mass merchandisers and clubs
  • Figure 28: U.S. mass merchandiser sales of gastrointestinal remedies, at current and constant prices,
• Supermarkets
  • Figure 29: U.S. supermarket sales of gastrointestinal remedies, at current and constant prices,
• The Consumer
• Introduction
• Summary
• Incidence and severity of gastrointestinal ailments
  • Figure 30: Incidence of GI ailments, by age, January-September 2005
  • Figure 31: Severity of GI ailments, by age, January-September 2005
• Prescription vs. OTC
  • Figure 32: Use of prescription vs. OTC product to treat GI ailment, by age, January-September 2005
• Types/kinds of OTC remedies preferred
  • Figure 33: Types/kinds of OTC GI remedies preferred, January-September 2005
• Brands preferred
  • Figure 34: Heartburn/indigestion aid brands preferred, January-September 2005
• Frequency of use of heartburn/indigestion aids
  • Figure 35: Frequency of use of heartburn/indigestion aids, by age, January-September 2005
• Use of laxatives and types preferred
  • Figure 36: Use of laxatives and types preferred, by age, January-September 2005
• Laxative brands preferred
  • Figure 37: Laxative brands preferred, January-September 2005
• Frequency of laxative use
  • Figure 38: Frequency of use of laxatives, by age, January-September 2005
• Attitudes towards GI ailments and remedies
  • Figure 39: Attitudes towards GI ailments, by age, August 2006
  • Figure 40: Alka-Seltzer ad featuring elderly consumers, 2006
  • Figure 41: Attitudes towards GI remedies, by age, August 2006
  • Figure 42: Self or doctor diagnosis of GI ailments, by problem, by age, August 2006
  • Figure 43: Effectiveness of OTC GI Remedies, by problem, by age, August 2006
• Cohort analysis
• Incidence of GI ailments among cohorts
  • Figure 44: Incidence of GI ailments, by cohort, January-September 2005
• Use of heartburn/indigestion aids and laxatives among cohorts
  • Figure 45: Use of heartburn/indigestion aids and laxatives, by cohort, January-September 2005
• Race/ethnicity analysis
• Incidence of GI ailments among ethnicities
  • Figure 46: Incidence of GI ailments, by race/ethnicity, January-September 2005
• Use of heartburn/indigestion aids and laxatives among ethnicities
  • Figure 47: Use of heartburn/indigestion aids and laxatives, by race/ethnicity, January-September 2005
• Attitudes towards GI ailments and remedies among ethnicities
  • Figure 48: Attitudes towards GI ailments, by race/ethnicity, August 2006
  • Figure 49: Attitudes towards GI remedies, by race/ethnicity, August 2006
• Future and Forecast
• Future trends
• Aging population continues to grow
  • Figure 50: Total U.S. population, by age, 2001-11
• Prescription switches forecast to increase
• Hispanics represent growing opportunity
  • Figure 51: U.S. Hispanic population, 2001, 2006, & 2011
• Prilosec protects its role in the market
• Retail pharmacy expands its healthcare role
• Market forecast
• Gastrointestinal remedies
  • Figure 52: Forecast of total U.S. FDM sales of gastrointestinal remedies, at current and constant
  • Figure 53: Graph: Forecast of total U.S. FDM sales of gastrointestinal remedies, at current and constant prices, 2006-11
• Antacids
  • Figure 54: Forecast of U.S. FDM sales of antacids, at current and constant prices, 2006-11
• Laxatives
  • Figure 55: Forecast of U.S. FDM sales of laxatives, at current and constant prices, 2006-11
• Stomach remedies
  • Figure 56: Forecast of U.S. FDM sales of stomach remedies, at current and constant prices, 2006-11
• Anti-diarrheals
  • Figure 57: Forecast of U.S. FDM sales of anti-diarrheals, at current and constant prices, 2006-11
• Forecast factors
• Appendix: Trade Associations
• Appendix: New Product Developments
• New product briefs
• McKesson: Sunmark Woman' s Laxative Tablets
• Procter & Gamble: Cinnamon Fiber Wafers
• Johnson & Johnson: Mylanta Ultimate Strength Antacid
• Pfizer: Rolaids Plus Antacid & Antigas Gas Relief
• GlaxoSmithKline: Gaviscon Extra Strength Antacid Extension
• Albertson' s: Equaline Milk of Magnesia